PURR
NASDAQ · Biotechnology
Hyperliquid Strategies
$8.49
-0.25 (-2.86%)
Open$8.78
Previous Close$8.74
Day High$8.87
Day Low$8.45
52W High$11.62
52W Low$3.01
Volume—
Avg Volume16.73M
Market Cap626.24M
P/E Ratio—
EPS—
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+99.6% upside
Current
$8.49
$8.49
Target
$16.95
$16.95
$12.34
$16.95 avg
$26.10
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 243.91M | 233.99M | 197.33M |
| Net Income | 21.63M | 22.04M | 17.71M |
| Profit Margin | 8.9% | 9.4% | 9.0% |
| EBITDA | 48.94M | 46.22M | 40.39M |
| Free Cash Flow | 24.46M | 20.15M | 20.27M |
| Rev Growth | -3.3% | +11.1% | +4.4% |
| Debt/Equity | 0.58 | 0.61 | 0.58 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $254.31 | +0.38% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $360.55 | +0.62% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.33 | -1.21% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $499.65 | +1.69% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $631.81 | -0.17% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $293.52 | +0.74% | 69.3 | 39.97B |